Kyowa Kirin Co., Ltd.
4 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Previously recorded as Kyowa Hakko Kirin Co., Ltd. (to 2019)
12
Ending by 2030
Nov 2026
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 30, 2026The maintenance fee for Substituted quinoxalines (US 9,067,923) comes due Dec 30, 2026. Unpaid by Jun 30, 2027, it lapses early.
- 4 fees due Jan 9 to 23, 2027 · next Jan 9
- 2 fees due Feb 11 to 13, 2027 · next Feb 11
- 5 fees due Apr 3 to 17, 2027 · next Apr 3
- 1 fee due May 19, 2027The maintenance fee for Method for Treating Pulmonary Hypertension with INTERLEUKIN-5 Receptor Antibody (US 10,479,836) comes due May 19, 2027. Unpaid by Nov 19, 2027, it lapses early.
- 2 fees due Jun 3 to 10, 2027 · next Jun 3
- 1 fee due Jul 7, 2027The maintenance fee for Compound as cationic lipid (US 10,525,138) comes due Jul 7, 2027. Unpaid by Jan 7, 2028, it lapses early.
- 2 fees due Aug 4, 2027
- 1 fee due Sep 22, 2027The maintenance fee for Anti FGF23 antibody and a pharmaceutical composition comprising the same (US 9,290,569) comes due Sep 22, 2027. Unpaid by Mar 22, 2028, it lapses early.
- 3 fees due Oct 9 to 30, 2027 · next Oct 9
- 2 fees due Nov 5 to 12, 2027 · next Nov 5
Recent changes
- 4 of the patents on this record were granted since Aug 20, 2026
- 2 terms have ended since Aug 20, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,851,478 | Agent for Preventing And/Or Treating Movement Disorder In force · High confidence | In force | High confidence | |
| US 7,504,104 | Human Cdr-Grafted Antibody and Antibody Fragment Thereof In force · Medium confidence | In force | Medium confidence | |
| US 7,727,993 | Administering adenosine A2A receptor antagonist to reduce or suppress side effects of parkinson's disease therapy In force · From the USPTO record | In force | From the USPTO record | |
| US 8,501,176 | Methods of Reducing Eosinophil Levels In force · High confidence | In force | High confidence | |
| US 9,815,895 | Methods of Reducing Basophil Levels In force · High confidence | In force | High confidence | |
| US 10,202,446 | Anti FGF23 antibody and a pharmaceutical composition comprising the same In force · From the USPTO record | In force | From the USPTO record | |
| US 11,192,953 | Human monoclonal antibody human CD134 (OX40) and methods of making and using same In force · From the USPTO record | In force | From the USPTO record | |
| US 12,319,741 | Human monoclonal antibody human CD134 (OX40) and methods of making and using same In force · From the USPTO record | In force | From the USPTO record | |
| US 10,646,544 | Pharmaceutical composition for treating bone diseases which comprises protein comprising Frizzled 1, Frizzled 2 or Frizzled 7 extracellular cysteine-rich domain In force · From the USPTO record | In force | From the USPTO record | |
| US 8,673,908 | Kynurenine production inhibitor In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 71: 4 patents in force now held by others · 18 lapsed for an unpaid fee · 9 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
17 pending · 3 abandoned · 15 no status recorded